Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Beckman Coulter; Lab21; Pacific Biometrics; Caprion Proteomics, Thallion Pharmaceuticals; FASEB

NEW YORK (GenomeWeb News) – Beckman Coulter this week set a preliminary 2010 guidance for adjusted earnings per share of between $4.40 and $4.55. According to Thomas Weisel Partners analyst Peter Lawson, the guidance is below analysts' consensus estimate of $4.56.

"While initial 2010 guidance was below consensus, we believe management is maintaining a conservative outlook on the Olympus synergies and economic conditions," he wrote in a research note published Thursday evening.

Beckman acquired Olympus' diagnostics business earlier this year for $780 million in a deal expected to expand Beckman's clinical chemistry offering with particular strength in the larger hospital laboratories.

UK molecular diagnostics testing services firm Lab21 will open its US headquarters in Greenville County, South Carolina, according to a statement issued this week by that state's Department of Commerce. The CLIA lab, with a particular focus on oncology testing, is expected to open early next year.

Pacific Biometrics this week announced that its shareholders have approved a change in the company's name to Pacific Biomarkers. It also said that shareholders had re-elected all seven members of its board of directors: Ronald Helm; Mario Ehlers; Paul Kana; Richard Palfreyman; Curtis Scheel; Stanley Schloz; and Kenneth Waters.

Caprion Proteomics has purchased back a subordinated promissory note from Thallion Pharmaceuticals for an immediate cash payment of $1,850,000. The promissory note was initially issued by Caprion in July 2007 as part of the proceeds from the sale of Thallion's proteomics business. Thallion said that it continues to retain its roughly 16 percent equity stake in Caprion.

The Federation of American Societies for Experimental Biology this week announced that the Genetics Society of America and the American Federation for Medical Research are the newest members of FASEB.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease, Study Finds

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer, Study Finds

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study says.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.